Medical Oncology Unit, Department of Systems Medicine, Tor Vergata Clinical Center University Hospital, Rome, Italy.
Anatomic Pathology Institute, Department of Biomedicine and Prevention, Tor Vergata University Hospital, Rome, Italy.
Crit Rev Oncol Hematol. 2017 Mar;111:133-143. doi: 10.1016/j.critrevonc.2017.01.016. Epub 2017 Jan 28.
Excision repair cross-complementation group 1 (ERCC1) is a key component in DNA repair mechanisms and may influence the tumor DNA-targeting effect of the chemotherapeutic agent oxaliplatin. Germline ERCC1 polymorphisms may alter the protein expression and published data on their predictive and prognostic value have so far been contradictory. In the present article we review available evidence on the clinical role and utility of ERCC1 polymorphisms and, in the absence of a 'perfect' trial, what we call the 'sliding doors' trial, we present the data of ERCC1 genotyping in our local patient population. We found a useful predictive value for oxaliplatin-induced risk of anemia.
切除修复交叉互补基因 1（ERCC1）是 DNA 修复机制中的关键组成部分，可能影响化疗药物奥沙利铂对肿瘤 DNA 的靶向作用。胚系 ERCC1 多态性可能改变蛋白表达，目前关于其预测和预后价值的研究结果尚存在争议。本文综述了 ERCC1 多态性的临床作用和实用性的现有证据，在缺乏“完美”试验的情况下，我们称之为“滑动门”试验，我们展示了我们本地患者人群中 ERCC1 基因分型的数据。我们发现 ERCC1 基因型对奥沙利铂诱导贫血风险有一定的预测价值。
